GENERAL COMMENTS
In this manuscript, Chen et al. describe the relationship of serum uric acid and atrial fibrillation in 8937 Chinese. The authors found that serum uric acid level is associated with the increase in prevalence of atrial fibrillation in these population. The present study is the observational, cross-sectional study, which observed the relationship between serum uric acid levels and the prevalence of atrial fibrillation. However, the findings of the study do not fully support the authors' conclusions and there are some points that the authors should address.
Specific comments: 1. Unfortunately, the specific purpose of the study is vaguely stated. What is the priority of this study? Previous studies have clearly shown the relationships between serum uric acid levels and the prevalence of atrial fibrillation. The authors should emphasize the novelty of the present study compared to the previous ones. 2. The authors emphasize the gender difference concerning the role of uric acid in atrial fibrillation in this study. However, I am afraid that different definition of hyperuricemia in women contributes to the results. How are the relationships between serum uric acid levels and the prevalence of atrial fibrillation using a definition of hyperuricemia as the serum uric acid of >7.0 mg/dL in women also? 3. Page 12, paragraph 2 and page 13, lines 1 and 2: This paragraph is speculative and therefore should be deleted since there is no data on gender-specific mechanisms concerning the role of uric acid in the prevalence of atrial fibrillation in this study. 4. Measurement of inflammatory markers that the authors listed in the paragraph 2 of page 12 would draw more specific conclusion of authors' hypothesis.
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GENERAL COMMENTS
1. This topic has already been extensively discussed in other studies [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] reaching similar conclusions of the ones in the submitted paper. Among the analysed papers in this revision, at least one [7] refers to Chinese population outpatients and has a similar design. A large meta-analysis of the previously published papers has already confirmed a potential association between serum uric acid (SUA) and atrial fibrillation (AF) [9] . However, authors state in page 5, line 41 that "For instance, several cross-sectional studies showed that elevated SUA levels were linked to a high risk of AF; however, these studies only enrolled hospital patients and not individuals from the general population". This sentence should be reformulated at the light of the generalpopulation studies performed on this topic. A female gender-specific mechanism has already been described in a previous work [13] .
I strongly suggest reviewing the paper by clarifying -both in introduction and discussion -what this paper really adds to current knowledge at the light of the already published papers.
2. A potential bias of the study is related to the selection of all the patients affected by AF in the sample, without screening for rheumatic disease, mitral valve stenosis, severe mitral valve insufficiency or other causes of valvular AF. Valvular AF is less frequent, but has different risk factors and different therapies and must be differentiated from non-valvular atrial fibrillation. In the current study, authors enrolled all the patients with electrocardiographic evidence of AF but do not state if they are considering patients with valvular or non-valvular AF. Moreover, authors analyse together patients with paroxysmal/persistent AF and subjects with permanent AF. Authors should review their paper, clarify their methods and comment on this issue.
3. Authors did perform any kind of a priori power analysis, which could have been be useful to better understand the effect size and the level of significance of the performed statistical analyses: this is of particular interest, since authors observed a very small number of patients affected by AF (53 subjects). In this study, author state arbitrarily that "A P value of < 0.05 (two-tailed) was considered statistically significant" (page 9, line 11). Since post-hoc power analysis should not routinely performed, authors should add a comment on this issue and analyse the width and the magnitude of the observed confidence intervals in order to give the reader informations on the statistical power of the study [14] .
4. Adjusted logistic regression analysis should be performed after covariate selection in order to reduce the risk of model overfitting, which is another potential source of bias. Covariate selection can be done with more classic approaches as univariate testing or logistic backwards elimination or newer techniques, such as penalised regressions (ridge or lasso regression) [15] . Authors should optimize their adjusted logistic regression model in order to prevent it from overfitting.
5. Also, I suggest testing the covariates for collinearity before adding them to an adjusted model. Collinear variables must be excluded in from the adjusted model, as potential sources of bias.
Some associations, such as eGFR/diuretics use or statins use/dyslipidaemia (adopted in Model 1/2/3), are at particular risk of collinearity and must be tested before inserting them in a multivariate logistic regression model. 6. Among the screened patients, authors included also subjects with stronger risk factors for AF, such as myocardial infarction and heart failure. It would be interesting to evaluate the prevalence of myocardial infarction and heart failure in the subpopulation of AFaffected patients and to check for significant differences in the prevalence of these factors between hyperuricemic and nonhyperuricemic patients. If a higher prevalence of myocardial infarction or heart failure is observed among patients with AF and hyperuricemia, authors should comment on this potential source of bias. I also suggest performing the logistic regression analysis by excluding patients affected by previous myocardial infarction or heart failure.
7. A table summarising the clinical characteristics of the AF-affected patients could be useful to show the differences of this subgroup from the screened population. 
VERSION 1 -AUTHOR RESPONSE
Reviewer 1: 1. Unfortunately, the specific purpose of the study is vaguely stated. What is the priority of this study? Previous studies have clearly shown the relationships between serum uric acid levels and the prevalence of atrial fibrillation. The authors should emphasize the novelty of the present study compared to the previous ones.
Response: Although previous studies have clearly shown the relationships between serum uric acid (SUA) and the prevalence of atrial fibrillation (AF), the effects of gender on the independent association between SUA and AF is not clear, and the samples of these clinical studies were relatively small. Hence, the effects of gender and the relatively large sample size are the novelty of the present study. We have modified the introduction of the study (see the Abstract and Strengths and Limitations of this study, page 5, lines 21-22, page 5, lines 1-2) 2. The authors emphasize the gender difference concerning the role of uric acid in atrial fibrillation in this study. However, I am afraid that different definition of hyperuricemia in women contributes to the results. How are the relationships between serum uric acid levels and the prevalence of atrial fibrillation using a definition of hyperuricemia as the serum uric acid of >7.0 mg/dL in women also? Response: Due to the difference of metabolic characteristics, hyperuricemia is defined differently between women and men. Our study defined hyperuricemia based on the NHANES-III laboratory definitions (see reference [19] ).
3. Page 12, paragraph 2 and page 13, lines 1 and 2: This paragraph is speculative and therefore should be deleted since there is no data on gender-specific mechanisms concerning the role of uric acid in the prevalence of atrial fibrillation in this study.
Response: This was a clinical cross-sectional study, and we demonstrated that SUA levels were significantly associated with AF prevalence in a particular Chinese population, but we were not able to elucidate the exact pathophysiologic and prognostic mechanisms underlying the link between SUA and AF. Therefore, we cited relevant references to speculate the potential mechanism. Despite this, the gender-specific mechanisms are still unclear, and the possible mechanism is potentially linked, in part, to menopause, as estrogen is known to be uricosuric. In our study, nearly one third of women (26.11%) were post-menopausal. Thus, we believe that age-related post-menopause potentially contributed to the possible mechanism underlying the gender difference. We have stated this issue in the present study, and we have included this as a limitation of our study (page 12, lines 4-6).
4. Measurement of inflammatory markers that the authors listed in the paragraph 2 of page 12 would draw more specific conclusion of authors' hypothesis. Response: Thank you for this valid point. However, this was a large cohort study, and we did not measure the inflammatory markers that we listed in paragraph 2 on page 12 during enrollment. Hence, we were unable to draw more specific conclusions related to our hypothesis.
Reviewer 2: 1.This topic has already been extensively discussed in other studies [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] reaching similar conclusions of the ones in the submitted paper. Among the analysed papers in this revision, at least one [7] refers to Chinese population outpatients and has a similar design. A large meta-analysis of the previously published papers has already confirmed a potential association between serum uric acid (SUA) and atrial fibrillation (AF) [9] . However, authors state in page 5, line 41 that "For instance, several cross-sectional studies showed that elevated SUA levels were linked to a high risk of AF; however, these studies only enrolled hospital patients and not individuals from the general population". This sentence should be reformulated at the light of the general-population studies performed on this topic. A female gender-specific mechanism has already been described in a previous work [13] . I strongly suggest reviewing the paper by clarifying -both in introduction and discussion -what this paper really adds to current knowledge at the light of the already published papers. Response: Thank you for pointing out this issue. We have modified the description, and we have clarified the conclusion of the previous study [13] in the Introduction and Discussion of the present study (page 5, lines 15-19; page 11, lines 19-22 ; page 12, line 1).
2. A potential bias of the study is related to the selection of all the patients affected by AF in the sample, without screening for rheumatic disease, mitral valve stenosis, severe mitral valve insufficiency or other causes of valvular AF. Valvular AF is less frequent, but has different risk factors and different therapies and must be differentiated from non-valvular atrial fibrillation. In the current study, authors enrolled all the patients with electrocardiographic evidence of AF but do not state if they are considering patients with valvular or non-valvular AF. Moreover, authors analyse together patients with paroxysmal/persistent AF and subjects with permanent AF. Authors should review their paper, clarify their methods and comment on this issue. Response: This was a large cohort study and rheumatic disease, mitral valve stenosis, severe mitral valve insufficiency, or other causes of valvular AF were not reported during enrollment. We therefore did not exclude the subjects with valvular AF, which may have generated potential bias. We have mentioned this as a limitation in the revised manuscript. The pathogenesis of paroxysmal and permanent AF is the same, but the severity of this disease is different. Hence, we believe that the risk factors of paroxysmal and permanent AF are the same and that it is not necessary to analyze patients with paroxysmal AF and subjects with permanent AF separately (page 13, lines 21-22).
3. Authors did perform any kind of a priori power analysis, which could have been be useful to better understand the effect size and the level of significance of the performed statistical analyses: this is of particular interest, since authors observed a very small number of patients affected by AF (53 subjects). In this study, author state arbitrarily that "A P value of < 0.05 (two-tailed) was considered statistically significant" (page 9, line 11). Since post-hoc power analysis should not routinely performed, authors should add a comment on this issue and analyse the width and the magnitude of the observed confidence intervals in order to give the reader informations on the statistical power of the study [14] . Response: We appreciate the reviewer's favorable comments and suggestions about our work. In the result section of the study, we showed that hyperuricemia correlated with AF after adjustment for various cardiovascular risk factors in all participants (P = 0.03, odds ratio (OR) = 2.051, 95% confidence interval (CI): 1.063 -3.856). This correlation was particularly stronger in women compared to men (P < 0.001, OR = 6.366, 95% CI: 2.553 -15.871 in women and P = 0.96, OR=1.025, 95% CI: 0.400 -2.626 in men). The width and the magnitude of the confidence intervals of total people and men are acceptable; however, the confidence intervals of women were relatively wide. This may be potentially attributed to the following: 1) AF prevalence was low due to the low mean age of the participants (42 years old); 2) AF prevalence was different between genders with hyperuricemia, as evidenced by AF prevalence being higher in women with hyperuricemia; 3) Although hyperuricemia was more prevalent in men (18% vs 8.4%, P < 0.001), hyperuricemia was associated with AF in women but not in men. Thus, gender affects the relationship between SUA and AF. Taken together, these reasons can collectively affect the width and magnitude of the confidence intervals. However, we agree that the conclusion of the study needs to be further corroborated in future studies (page 11, lines 8-15).
4. Adjusted logistic regression analysis should be performed after covariate selection in order to reduce the risk of model overfitting, which is another potential source of bias. Covariate selection can be done with more classic approaches as univariate testing or logistic backwards elimination or newer techniques, such as penalised regressions (ridge or lasso regression) [15] . Authors should optimize their adjusted logistic regression model in order to prevent it from overfitting. Response: We apologize for not clearly describing our statistical method. In our statistical analysis, we first used the univariate testing to filter out the significant covariates, then further used the multivariable logistic regression to analyze the associations between SUA and AF. We have modified this portion of statistical analysis (page 9, line 4). 5. Also, I suggest testing the covariates for collinearity before adding them to an adjusted model. Collinear variables must be excluded in from the adjusted model, as potential sources of bias. Some associations, such as eGFR/diuretics use or statins use/dyslipidaemia (adopted in Model 1/2/3), are at particular risk of collinearity and must be tested before inserting them in a multivariate logistic regression model. Response: We used collinearity analysis of variables prior to logistic regression analysis, which showed that eGFR and BMI were collinear variables, and thus were excluded from the adjusted model. We also analyzed the associations between SUA and AF prevalence, and found nearly identical results (page 9, lines 2-4).
6. Among the screened patients, authors included also subjects with stronger risk factors for AF, such as myocardial infarction and heart failure. It would be interesting to evaluate the prevalence of myocardial infarction and heart failure in the subpopulation of AF-affected patients and to check for significant differences in the prevalence of these factors between hyperuricemic and nonhyperuricemic patients. If a higher prevalence of myocardial infarction or heart failure is observed among patients with AF and hyperuricemia, authors should comment on this potential source of bias. I also suggest performing the logistic regression analysis by excluding patients affected by previous myocardial infarction or heart failure. Response: We appreciate the reviewer's favorable comments and suggestions about our work. We have checked for significant differences in the prevalence of myocardial infarction and heart failure between hyperuricemic and nonhyperuricemic patients: myocardial infarction (P = 0.49) and heart failure (P = 0.24). There was no significant difference in these factors between the two groups. We further added Table 3 to show the differences of clinical characteristics between the AF group and non-AF group. Myocardial infarction and heart failure were more prevalent in the subjects with AF (all P < 0.001). We excluded participants with myocardial infarction or heart failure, then conducted a sensitivity analysis to evaluate the relationship between SUA and AF. We found a nearly identical result. Thus, the difference in the prevalence of myocardial infarction and heart failure between the AF group and non-AF group did not affect our conclusions. A number of factors, including advancing age, male gender, obesity, hypertension, congestive heart failure, myocardial infarction, chronic kidney disease, and diabetes mellitus, have been identified as risk factors for AF development. We therefore believe that our logistic regression analysis should include subjects with heart failure or myocardial infarction. In addition, sensitivity analysis strengthened our findings (Table 2, Table 3 ). 7. A table summarising the clinical characteristics of the AF-affected patients could be useful to show the differences of this subgroup from the screened population. Response: As suggested, the clinical characteristics between the AF group and non-AFgroup are presented in Table 2 .
